BCL2 and B-cell chronic lymphocytic leukemia: ABT-199 (venetoclax), a BCL2 specific inhibitor, was first approved for treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia8–10, and has shown significant clinical activity in CLL regardless of genotype11.